Treace to Present at Stifel 2023 Healthcare Conference
2023年10月30日 - 8:00PM
Treace Medical Concepts, Inc. (“Treace” or the “Company”)
(NasdaqGS: TMCI), a medical technology company driving a
fundamental shift in the surgical treatment of hallux valgus
(commonly known as bunions) through its Lapiplasty® 3D Bunion
Correction® Procedure, today announced that John T. Treace, Chief
Executive Officer, and Mark L. Hair, Chief Financial Officer, will
participate in a fireside chat at the Stifel 2023 Healthcare
Conference on Tuesday, November 14, 2023, beginning at
approximately 8:35 am ET.
A live webcast and replay of the fireside chat
will be available on the Company’s investor relations website at
https://investors.treace.com/.
Internet Posting of Information
Treace routinely posts information that may be
important to investors in the “Investor Relations” section of its
website at www.treace.com. The company encourages investors and
potential investors to consult the Treace website regularly for
important information about Treace.
About Treace Medical
ConceptsTreace Medical Concepts, Inc. is a medical
technology company with the goal of advancing the standard of care
for the surgical management of bunion and related midfoot
deformities. Bunions are complex 3-dimensional deformities that
originate from an unstable joint in the middle of the foot and
affect approximately 65 million Americans, of which Treace
estimates 1.1 million are annual surgical candidates. Treace has
pioneered and patented the Lapiplasty® 3D Bunion Correction® System
– a combination of instruments, implants, and surgical methods
designed to surgically correct all 3 planes of the bunion deformity
and secure the unstable joint, addressing the root cause of the
bunion and helping patients get back to their active lifestyles.
Treace expanded its offering with the Adductoplasty® Midfoot
Correction System, designed for reproducible surgical correction of
the midfoot to provide further support to hallux valgus patients,
and the Hammertoe PEEK Fixation System, designed to address
hammertoe, claw toe and mallet toe deformities. For more
information, please visit www.treace.com.
To learn more about Treace, connect with us on
LinkedIn, Twitter, Facebook and Instagram.
Contacts:
Treace Medical ConceptsJulie Dewey, IRCChief
Communications & Investor Relations Officerjddewey@treace.com |
209-613-6945
Treace Medical Concepts (NASDAQ:TMCI)
過去 株価チャート
から 4 2024 まで 5 2024
Treace Medical Concepts (NASDAQ:TMCI)
過去 株価チャート
から 5 2023 まで 5 2024